Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea

BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting β(2)-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Yum, Ho-Kee, Kim, Hak-Ryul, Chang, Yoon Soo, Shin, Kyeong-Cheol, Kim, Song, Oh, Yeon-Mok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256353/
https://www.ncbi.nlm.nih.gov/pubmed/28119747
http://dx.doi.org/10.4046/trd.2017.80.1.52

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256353/
https://www.ncbi.nlm.nih.gov/pubmed/28119747
http://dx.doi.org/10.4046/trd.2017.80.1.52

Ejemplares similares